Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 12/20 | 0.52 |
| ▸ | CA1 | P00915 | 11/20 | 0.52 |
| ▸ | CA9 | Q16790 | 11/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 10/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2237057 | 0.78 | CA2 (0.74) | KDM4ECA2CA1CA9CA12 | |
| SCHEMBL3063622 | 0.78 | ALDH1A1 (0.65) | KDM4EGAAMAPTALDH1A1LMNA | |
| SCHEMBL14725328 | 0.77 | KDM4E (0.60) | KDM4EGAAMAPTALDH1A1MAPK1 | |
| SCHEMBL9779693 | 0.75 | GAA (0.67) | KDM4EGAAMAPTALDH1A1LMNA | |
| SCHEMBL2236429 | 0.74 | GAA (0.66) | KDM4EGAAMAPTALDH1A1MAPK1 | |
| SCHEMBL28761619 | 0.74 | KDM4E (1.00) | KDM4ECA1CA9GAAMAPT | |
| SCHEMBL2237481 | 0.73 | CA1 (0.60) | CA2CA1CA9CA12ALDH1A1 | |
| SCHEMBL2235284 | 0.73 | CA1 (0.72) | CA2CA1CA9CA12 | |
| SCHEMBL8611437 | 0.72 | GAA (0.64) | KDM4EGAAMAPTALDH1A1MAPK1 | |
| SCHEMBL5448347 | 0.72 | GAA (0.64) | KDM4EGAAMAPTALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130053392-A1 | CARBONIC ANHYDRASE INHIBITORS | UNIVERSITETET I OSLO (NO) | 2013-02-28 | — | — | US | disclosed |
| US-20130053392-A1 | CARBONIC ANHYDRASE INHIBITORS | UNIVERSITETET I OSLO (NO) | 2013-02-28 | — | — | US | disclosed |
| EP-2533775-A1 | CARBONIC ANHYDRASE INHIBITORS | Universita' Degli Studi di Firenze (IT) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011098610-A1 | CARBONIC ANHYDRASE INHIBITORS | UNIVERSITA DEGLI STUDI DI FIRENZE (IT) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053392-A1 | CARBONIC ANHYDRASE INHIBITORS | CA9, CA2, CA4 | KDM4E 822/4885CA2 2/4885CA1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.